Cargando…
PPARγ agonist-loaded PLGA-PEG nanocarriers as a potential treatment for Alzheimer’s disease: in vitro and in vivo studies
OBJECTIVE: The first aim of this study was to develop a nanocarrier that could transport the peroxisome proliferator-activated receptor agonist, pioglitazone (PGZ) across brain endothelium and examine the mechanism of nanoparticle transcytosis. The second aim was to determine whether these nanocarri...
Autores principales: | Silva-Abreu, Marcelle, Calpena, Ana Cristina, Andrés-Benito, Pol, Aso, Ester, Romero, Ignacio A, Roig-Carles, David, Gromnicova, Radka, Espina, Marta, Ferrer, Isidre, García, María Luisa, Male, David |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6154713/ https://www.ncbi.nlm.nih.gov/pubmed/30271148 http://dx.doi.org/10.2147/IJN.S171490 |
Ejemplares similares
-
Nanocarriers for Delivery of Oligonucleotides to the CNS
por: Male, David, et al.
Publicado: (2022) -
Assessment of Efficacy and Safety Using PPAR-γ Agonist-Loaded Nanocarriers for Inflammatory Eye Diseases
por: Miralles, Esther, et al.
Publicado: (2022) -
Gold nanocarriers for transport of oligonucleotides across brain endothelial cells
por: Fatima, Nayab, et al.
Publicado: (2020) -
Role of hydroxypropyl-β-cyclodextrin on freeze-dried and gamma-irradiated PLGA and PLGA–PEG diblock copolymer nanospheres for ophthalmic flurbiprofen delivery
por: Vega, Estefanía, et al.
Publicado: (2012) -
PPARγ Agonist-Loaded PLGA-PEG Nanocarriers as a Potential Treatment for Alzheimer’s Disease: In vitro and in vivo Studies [Corrigendum]
Publicado: (2023)